瑞格列奈或格列吡嗪联合甘精胰岛素治疗初诊2型糖尿病的观察

Clinical observation of repaglinide or glipizide combined with glargine in the treatment of newly diagnosed type 2 diabetic patients

目的比较瑞格列奈或格列吡嗪联合甘精胰岛素治疗对初诊2型糖尿病患者降糖的疗效及对β细胞功能的影响。方法将笔者所在医院门诊初诊的2型糖尿病患者45例,随机分成瑞格列奈组(瑞格列奈+甘精胰岛素,n=23)和格列吡嗪组(格列吡嗪+甘精胰岛素,n=22)。结果两组治疗3个月后餐前和餐后的末梢血糖及HbAlc均较治疗前明显下降(P<0.01)。结论瑞格列奈(1 mg,3次/d)联合甘精胰岛素控制餐后血糖、HbAlc和改善胰岛β细胞分泌功能较格列吡嗪(5 mg,1次/d)联合组更好。

Objective The effects of repaglinide or glipizide combined with glargine on glucose metabolism and β - cell function were observed in the patients with newly diagnosed type 2 diabetes. Methods The 45 patients with newly diagnosed type 2 were randomly divided in to Repaglinide group （ Repaglinide ＋ Glargine; n = 23 ） and Glipizide group （Glipizide ＋ Glargine ;n = 22）. Results The preprandial capillary blood glucose, postprandial capillary blood glucose and HbAlc in both groups after 3 -month treatment were significantly reduced as compared with those at baseline（ P 〈 0.01 ）. Conclusion The treatment with repaglinide （1 mg, tid） plus glargine was more efficient than glipizide （5 mg, qd ） plus glargine in improving β - cell functiou, ameliorating HbA1 c and postprandial blood, glucose excursions in patients with type 2 diabetes.